Hepatitis B: Progress in the last 15 years

Combination Therapy in Liver Transplant Recipients with Hepatitis B Virus Without Hepatitis B Immune Globulin

“…Despite these economic concerns, centers throughout the world continue to use HBIg for prophylaxis and continue it for the lifetime of the liver transplant (LTx) recipient. Discussions pertaining to drug discontinuation are sparse, while the most common concerns regarding HBIg therapy are related to the duration of therapy [4,12]. Regimens that are cost-effective and safe will require investigation, in particular, for the hepatitis B patient with a negative viral load at the time of LTx.…”

Recipient cytotoxic T lymphocyte antigen‐4 +49 G/G genotype is associated with reduced incidence of hepatitis B virus recurrence after liver transplantation among Chinese patients

“…However, HBV reinfection after LT is a frequent clinical problem. Despite the prophylactic use of hepatitis B immune globulin (HBIG) and nucleoside analogous lamivudine (LAM), the incidence of HBV recurrence was reported to be 0-10% even in most distinguished centres (1,2). In this respect, the administration of various anti-HBV regimens was not the only factor to influence HBV recurrence.…”

Prevelance of Common YMDD Motif Mutations in Long Term Treated Chronic HBV Infections in a Turkish Population

“…In the prolonged administration of LVD usually is necessary to obtain significant clinical benefits, but at the same time, the risk for developing drug-resistant mutations increases with duration of therapy (Villamil, 2002;Kim et al, 2012). Longterm LVD therapy can usually supress HBV replication, however prolonged mono therapy leads to the lamivudine resistant HBV (Balzarini et al, 2013).…”